Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.
about
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaHsp90 Inhibitors for the Treatment of Chronic Myeloid LeukemiaRisk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase InhibitorsLong-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.Selecting the best frontline treatment in chronic myeloid leukemiaTyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous LeukemiaImatinib attenuates cardiac fibrosis by inhibiting platelet-derived growth factor receptors activation in isoproterenol induced model.Targeting EZH2 for cancer therapy: progress and perspective.Bosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects.Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis.Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.Chronic myeloid leukemia: Second-line drugs of choice.The Safety of Bosutinib for the Treatment of Chronic Myeloid Leukemia.Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome.Bosutinib for Chronic Myeloid Leukemia.First line treatment with newer tyrosine kinase inhibitors in chronic myeloid leukemia associated with deep and durable molecular response - systematic review and meta-analysis.Bosutinib induced pleural effusions: Case report and review of tyrosine kinase inhibitors induced pulmonary toxicity.Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trialLong-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinibBosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease.Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial.Precision oncology: neither a silver bullet nor a dream.Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?Practical Management of Toxicities Associated With Bosutinib in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?Bosutinib in chronic myeloid leukemia: patient selection and perspectives.Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia.Bosutinib, a Lyn/Btk inhibiting tyrosine kinase inhibitor, is ineffective in advanced systemic mastocytosis.Cardiologist's perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.
P2860
Q26749324-7B7F6582-4099-4C9F-9BA9-79DE13239DDDQ26771790-99D36008-4AFC-4E57-81DC-359FCAC4D033Q26851417-16BA910F-EC9F-4A77-A1B5-D28077E0CE0BQ33434675-7AA50DB9-B772-4D74-8251-859AD8471F42Q33764253-111370B6-3120-4F89-819B-5CCF2F24F4FCQ33806617-11724491-CF26-46B4-8281-946AF111976FQ36389384-178258CA-2860-405C-A73F-8FCBB095890CQ37204063-AE0DD7ED-35A9-4C82-A723-01C958A3F2C3Q37579983-7226DDB0-A640-4FD8-AD7F-78CA67C97C5CQ38363058-4556D03F-3A11-42E5-BA51-D23BC070E11BQ38457554-BF8D952F-2484-4BBA-8557-B2CDC20BFA1DQ38587453-52B720D2-8F73-425F-9D25-50C51E7B19B8Q38604104-33263D86-B8D7-4C5D-A9A8-31E50C6F1D50Q38640422-A6E3DAF5-15C8-4872-9E4B-40CE605C83E3Q38642952-EF32D8B1-787A-434F-A3A1-A926374023A7Q38707841-AA468F5B-E233-413B-8F15-483B8A77DBF8Q38797683-8B3B2257-5F10-4F7A-8D02-96F95065C178Q38835127-D985F7B3-FD0E-4F16-AA1D-5DD1ADEA035EQ38936993-50717F3F-7F83-44BB-992C-040FBB4E31E8Q39339523-3BE2BD30-0B99-44FE-A3B3-2D7BB8C22FF8Q40807968-A74B2A74-D84E-40D6-8C32-92C3E5CDAE35Q41304682-B3330FB1-DDE8-47E2-A07D-874E60DE357BQ46220838-50230936-3A67-4870-B8AA-C71BC3946DAEQ47706936-B4C387B3-E9A6-4FFC-B3F2-99921A71EF89Q47737073-A7DF8026-BDA4-41BE-8885-26EC391B772FQ48320624-3DE27F46-7DC9-4575-A792-C51A63B84275Q49553324-E98C03B2-7BA5-4A6C-8802-E7F21A4ED8EFQ49887884-4CE36ED2-023F-42F4-8EDB-9E09E487D31CQ50997822-8BD401DC-FA1E-4983-B06D-09266D39272AQ52562694-08E8F904-B246-4043-9F4E-11D650157881Q52571134-B55B86D5-DF6C-43E6-B205-01EA139667AEQ52970799-5FEDE8D1-FE8B-47D1-B922-34DE501C1045Q53129924-FE477C5B-0016-40D1-B323-031EF3D57AC9
P2860
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Safety of bosutinib versus ima ...... hase chronic myeloid leukemia.
@ast
Safety of bosutinib versus ima ...... hase chronic myeloid leukemia.
@en
type
label
Safety of bosutinib versus ima ...... hase chronic myeloid leukemia.
@ast
Safety of bosutinib versus ima ...... hase chronic myeloid leukemia.
@en
prefLabel
Safety of bosutinib versus ima ...... hase chronic myeloid leukemia.
@ast
Safety of bosutinib versus ima ...... hase chronic myeloid leukemia.
@en
P2093
P2860
P50
P921
P356
P1476
Safety of bosutinib versus ima ...... hase chronic myeloid leukemia.
@en
P2093
Dmitri Pavlov
Jeff H Lipton
Karin Gogat Marchant
Ladan Duvillié
Navin Khattry
Tim H Brümmendorf
Victor Rossiev
P2860
P304
P356
10.1002/AJH.23788
P50
P577
2014-07-21T00:00:00Z